Viatris to acquire Pacira BioSciences for $36.50/share cash, $1.65B equity value

Pacira BioSciences, Inc.

Viatris agreed to acquire Pacira for $36.50/share in cash, aggregate equity value $1.65B; tender offer to commence within 15 business days.
Pacira generated approximately $746M total revenue and approximately $177M adjusted EBITDA for the last twelve months ended June 30, 2026.
Deal adds EXPAREL (bupivacaine liposome) and ZILRETTA (triamcinolone acetonide) non-opioid pain products; expected close by end of 2026.
Viatris expects immediate accretion to guidance metrics; funded primarily from excess cash with remainder short-term borrowings; minimal impact on gross leverage ratio.
Pacira would pay $62.0M termination fee if it accepts a superior offer; merger under Delaware Section 251(h), no shareholder vote required.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.